
Hepion Pharmaceuticals, Inc.
63
Recent SEC filings include amendments to corporate structure and financing agreements. No direct recent news coverage specifically about Hepion Pharmaceuticals was identified, but broader industry and market news provide context.
- The company filed a Membership Interest Purchase Agreement and amendments to its Certificate of Incorporation in October 2026, indicating corporate restructuring activities [S2].
- Convertible note and warrant agreements were filed in September 2026, reflecting recent financing activities [S2].
- No material changes to risk factors were reported in the latest quarterly filing compared to the prior annual filing [S2].
Hepion Pharmaceuticals, Inc. is a publicly reporting company with recent SEC filings including a 10-K and a 10-Q/A. The company reported a net loss and negative earnings per share for the third quarter of 2026. It maintains a strong liquidity position with current assets exceeding current liabilities by a significant margin as of September 30, 2026. The company has ongoing financing and management arrangements as indicated by recent exhibits filed with the SEC. Publicly available information on the company's detailed business model, sector, and industry classification is limited.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Hepion Pharmaceuticals, Inc. reported a net loss of approximately $4.58 million for the three months ended September 30, 2026, with a strong liquidity position indicated by a current ratio of 4.43 and a cash ratio of 12.49 as of the same date [S2].
The company maintains a strong liquidity position with a current ratio of 4.43 and a cash ratio of 12.49 as of September 30, 2026, which supports operational flexibility. Recent SEC filings indicate active management of financing instruments such as convertible notes and warrants, which may provide capital resources. The absence of material changes in risk factors suggests stability in the company's risk profile [S2].
Hepion Pharmaceuticals reported a net loss of approximately $4.58 million for the three months ended September 30, 2026, with negative earnings per share, indicating ongoing operating losses. Limited public disclosure on business operations and sector specifics reduces transparency. The company’s financial performance and business model details remain unclear, which may pose challenges for stakeholder assessment.
There is insufficient publicly disclosed information to assess Hepion Pharmaceuticals' competitive advantages or moat. The company operates in the pharmaceutical sector, which typically involves intellectual property and regulatory barriers, but specific details are not disclosed in the available filings or news.
• Operating Losses: The company reported a net loss and negative earnings per share for the recent quarter, indicating ongoing operating expenses exceeding revenues.
• Limited Business Model Disclosure: Public information on the company's detailed business model, sector, and industry classification is limited, reducing visibility into operational risks and opportunities.
• Dependence on Financing: Recent SEC exhibits indicate reliance on convertible notes and warrants, suggesting dependence on external financing which may dilute existing shareholders or increase financial risk.
Business trends: The company continues to report operating losses while maintaining strong liquidity ratios, with no material changes in disclosed risk factors.
Execution milestones: Recent SEC filings include corporate restructuring and financing agreements, reflecting active management of capital structure.
Key risks: Ongoing operating losses, limited transparency on business operations, and reliance on external financing instruments pose challenges.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Hepion Pharmaceuticals, Inc. is a publicly reporting company with recent SEC filings including a 10-K and a 10-Q/A as of November 17, 2026.
- As of September 30, 2026, the company reported current assets of approximately $4.94 million and current liabilities of approximately $1.11 million, resulting in a current ratio of 4.43 and a cash ratio of 12.49, indicating strong short-term liquidity.
- Cash and cash equivalents reported as of December 31, 2019, were approximately $13.92 million.
- For the three months ended September 30, 2026, Hepion Pharmaceuticals reported a net loss of approximately $4.58 million and basic and diluted earnings per share of -$0.06.
- There have been no material changes to risk factors since the 2025 Form 10-K filing.
- Recent SEC filings include exhibits related to convertible notes, warrants, and employment agreements, indicating ongoing corporate financing and management arrangements.
- Recent news coverage does not directly mention Hepion Pharmaceuticals but includes industry and market context relevant to biotechnology and pharmaceuticals.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Generated 2026-11-17
- S1 | 2026-03-11 | 10-K
- S2 | 2026-11-17 | 10-Q/A
- N1 | 2026-11-17 | www.nasdaq.com | Upcoming Dividend Run For ICL? | https://www.nasdaq.com/articles/upcoming-dividend-run-icl
- N2 | 2026-11-17 | www.nasdaq.com | Upcoming Dividend Run For DSWL? | https://www.nasdaq.com/articles/upcoming-dividend-run-dswl
- N3 | 2026-11-17 | www.nasdaq.com | ETF Launch Boom, Closure Bust: How to Spot a Fund That Might Not Last | https://www.nasdaq.com/articles/etf-launch-boom-closure-bust-how-spot-fund-might-not-last
- N4 | 2026-11-17 | www.nasdaq.com | U.S. Industrial Production Unexpectedly Decreases In October | https://www.nasdaq.com/articles/us-industrial-production-unexpectedly-decreases-october
- N5 | 2026-11-17 | www.nasdaq.com | ProMIS Licenses TXP1 From Ossianix To Deliver Alzheimer's & Parkinson's Therapies To Brain | https://www.nasdaq.com/articles/promis-licenses-txp1-ossianix-deliver-alzheimers-parkinsons-therapies-brain
- N6 | 2026-11-17 | www.nasdaq.com | Uber Partners With Kohl's To Launch Nationwide On-Demand Delivery | https://www.nasdaq.com/articles/uber-partners-kohls-launch-nationwide-demand-delivery
- N7 | 2026-11-17 | www.nasdaq.com | SELLAS Life Sciences Group, Inc. Announces Positive Phase 3 REGAL Trial Results for Galinpepimut-S | https://www.nasdaq.com/articles/sellas-life-sciences-group-inc-announces-positive-phase-3-regal-trial-results-galinpepimut
- N8 | 2026-11-17 | www.nasdaq.com | OneWater Marine Inc. Reports Fiscal Year 2026 Revenue of $1,779.6 million and Net Loss of $(8.4) million | https://www.nasdaq.com/articles/onewater-marine-inc-reports-fiscal-year-2026-revenue-17796-million-and-net-loss-84-million
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


